Saturday 17 October 2026
Export NEPH’s income statement to Excel — free account
Nephros Inc.
NEPH Healthcare Medical Instruments & Supplies
Nephros Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.8 million, up 32.7% from fiscal 2024. In the quarter to June 2026, revenue grew 36.2%, EPS grew 450.0% and free cash flow fell 31.5%, each against the same quarter a year earlier.
3.65
0.14
+3.99%
Follow NEPH
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
22.91 | 45.29 | 46.12 | 36.38 |
+8 more quarters Free account |
P/S ratio |
1.87 | 1.66 | 2.76 | 2.80 | |
P/FCF ratio |
0.00 | 0.00 | 34.07 | 19.35 | |
P/Operating CF |
56.92 | (18.99) | 225.16 | 507.02 | |
P/B ratio |
3.24 | 2.97 | 5.08 | 5.02 | |
Price to Tangible BV |
3.60 | 3.35 | 5.78 | 5.74 | |
EV/Sales |
1.64 | 1.45 | 2.47 | 2.51 | |
EV/EBITDA |
19.32 | 34.53 | 36.10 | 28.37 | |
EV/Operating CF |
(51.54) | (79.68) | 28.20 | 16.56 | |
EV/FCF |
(43.34) | (58.62) | 30.52 | 17.36 | |
Quick Ratio |
2.63 | 2.98 | 2.82 | 3.17 | |
Current Ratio |
4.07 | 4.55 | 4.06 | 4.34 | |
Net Debt/EBITDA |
(3.78) | (32.40) | (108.00) | (14.86) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.48 | 1.50 | 1.51 | 1.52 | |
Operating CF/Net income |
0.57 | (11.94) | 3.71 | 0.29 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
1,213.00 | — | — | — | |
Research and Development Expense of Revenue |
6.08% | 6.64% | 8.35% | 7.09% | |
Selling, General and Administrative Expense of Revenue |
40.19% | 48.37% | 48.97% | 46.79% | |
Intangible Assets out of Total Assets |
0.08 | 0.09 | 0.09 | 0.10 | |
Share Based Compensation of Revenue |
1.01% | 1.15% | 1.67% | 1.47% | |
Graham Net Nets |
0.25 | 0.26 | 0.15 | 0.15 | |
Graham Number |
1.97 | 1.22 | 1.51 | 1.66 | |
Earnings Yield |
4.36% | 2.21% | 2.17% | 2.75% | |
Free Cash Flow Yield |
(2.03%) | (1.49%) | 2.94% | 5.17% | |
Revenue per Share |
0.55 | 0.49 | 0.45 | 0.45 | |
Operating CF per Share |
0.06 | (0.16) | 0.02 | 0.01 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.06 | (0.16) | 0.02 | 0.01 | |
Cash per Share |
0.43 | 0.38 | 0.51 | 0.49 | |
Shareholders Equity per Share |
1.10 | 1.00 | 0.96 | 0.94 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.10 | 1.00 | 0.96 | 0.94 | |
Free Cash Flow |
0.68 | (1.67) | 0.23 | 0.10 | |
Working Capital |
10.25 | 8.97 | 8.46 | 8.24 | |
Net Current Asset Value |
9.79 | 8.40 | 7.78 | 7.47 | |
EV/EBIT |
20.75 | 40.96 | 40.48 | 31.16 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
23.61 | 46.88 | 45.19 | 34.74 | |
| Other line items | |||||
Average Receivables |
3.07 | 3.10 | 2.10 | 2.18 | |
Average Payables |
1.30 | 1.01 | 0.78 | 0.67 | |
Average Inventory |
3.39 | 2.79 | 2.92 | 2.92 | |
Average Assets |
14.01 | 12.79 | 12.43 | 11.82 | |
Average Common Equity |
10.78 | 10.00 | 9.39 | 9.09 |
Columns are period end dates